Guidelines for COVID-19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients

Alpana Waghmare; Maheen Z. Abidi; Michael Boeckh; Roy F. Chemaly; Sanjeet Dadwal; Zeinab El Boghdadly; Mini Kamboj; Genovefa A. Papanicolaou; Steven A. Pergam; Zainab Shahid

doi:10.1016/j.bbmt.2020.07.027

Guidelines for COVID-19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients

Alpana Waghmare, Maheen Z. Abidi, Michael Boeckh, Roy F. Chemaly, Sanjeet Dadwal, Zeinab El Boghdadly, Mini Kamboj, Genovefa A. Papanicolaou, Steven A. Pergam, Zainab Shahid

Infectious Diseases, Infection Control, and Employee Health

Research output: Contribution to journal › Article › peer-review

46 Scopus citations

Abstract

There are currently limited data on the epidemiology, clinical manifestations, and optimal management of Coronavirus Disease 2019 (COVID-19) in hematopoietic cell transplantation and cellular therapy recipients. Given the experience with other respiratory viruses, we anticipate that patients may develop severe clinical disease and thus provide the following general principles for cancer centers across the nation. These guidelines were developed by members of the American Society for Transplantation and Cellular Therapy Infectious Diseases Special Interest Group. Specific practices may vary depending on local epidemiology and testing capacity, and the guidance provided in this document may change as new information becomes available.

Original language	English (US)
Pages (from-to)	1983-1994
Number of pages	12
Journal	Biology of Blood and Marrow Transplantation
Volume	26
Issue number	11
DOIs	https://doi.org/10.1016/j.bbmt.2020.07.027
State	Published - Nov 2020

Keywords

COVID-19
SARS-CoV-2
cellular therapy
hematopoietic cell transplan

ASJC Scopus subject areas

Hematology
Transplantation

Access to Document

10.1016/j.bbmt.2020.07.027

Cite this

@article{f91ec25a7b2e48949eb6a2ac1a9c1e99,

title = "Guidelines for COVID-19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients",

abstract = "There are currently limited data on the epidemiology, clinical manifestations, and optimal management of Coronavirus Disease 2019 (COVID-19) in hematopoietic cell transplantation and cellular therapy recipients. Given the experience with other respiratory viruses, we anticipate that patients may develop severe clinical disease and thus provide the following general principles for cancer centers across the nation. These guidelines were developed by members of the American Society for Transplantation and Cellular Therapy Infectious Diseases Special Interest Group. Specific practices may vary depending on local epidemiology and testing capacity, and the guidance provided in this document may change as new information becomes available.",

keywords = "COVID-19, SARS-CoV-2, cellular therapy, hematopoietic cell transplan",

author = "Alpana Waghmare and Abidi, {Maheen Z.} and Michael Boeckh and Chemaly, {Roy F.} and Sanjeet Dadwal and {El Boghdadly}, Zeinab and Mini Kamboj and Papanicolaou, {Genovefa A.} and Pergam, {Steven A.} and Zainab Shahid",

note = "Publisher Copyright: {\textcopyright} 2020 American Society for Transplantation and Cellular Therapy",

year = "2020",

month = nov,

doi = "10.1016/j.bbmt.2020.07.027",

language = "English (US)",

volume = "26",

pages = "1983--1994",

journal = "Biology of Blood and Marrow Transplantation",

issn = "1083-8791",

publisher = "Elsevier Inc.",

number = "11",

}

TY - JOUR

T1 - Guidelines for COVID-19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients

AU - Waghmare, Alpana

AU - Abidi, Maheen Z.

AU - Boeckh, Michael

AU - Chemaly, Roy F.

AU - Dadwal, Sanjeet

AU - El Boghdadly, Zeinab

AU - Kamboj, Mini

AU - Papanicolaou, Genovefa A.

AU - Pergam, Steven A.

AU - Shahid, Zainab

PY - 2020/11

Y1 - 2020/11

N2 - There are currently limited data on the epidemiology, clinical manifestations, and optimal management of Coronavirus Disease 2019 (COVID-19) in hematopoietic cell transplantation and cellular therapy recipients. Given the experience with other respiratory viruses, we anticipate that patients may develop severe clinical disease and thus provide the following general principles for cancer centers across the nation. These guidelines were developed by members of the American Society for Transplantation and Cellular Therapy Infectious Diseases Special Interest Group. Specific practices may vary depending on local epidemiology and testing capacity, and the guidance provided in this document may change as new information becomes available.

AB - There are currently limited data on the epidemiology, clinical manifestations, and optimal management of Coronavirus Disease 2019 (COVID-19) in hematopoietic cell transplantation and cellular therapy recipients. Given the experience with other respiratory viruses, we anticipate that patients may develop severe clinical disease and thus provide the following general principles for cancer centers across the nation. These guidelines were developed by members of the American Society for Transplantation and Cellular Therapy Infectious Diseases Special Interest Group. Specific practices may vary depending on local epidemiology and testing capacity, and the guidance provided in this document may change as new information becomes available.

KW - COVID-19

KW - SARS-CoV-2

KW - cellular therapy

KW - hematopoietic cell transplan

UR - http://www.scopus.com/inward/record.url?scp=85089457585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85089457585&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2020.07.027

DO - 10.1016/j.bbmt.2020.07.027

M3 - Article

C2 - 32736007

AN - SCOPUS:85089457585

SN - 1083-8791

VL - 26

SP - 1983

EP - 1994

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

IS - 11

ER -

Guidelines for COVID-19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this